FDA Drug Safety Communication: Safety Review update on reports of Hepatosplenic T-Cell Lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine
Links shared publicly online about this topic.
- 365total visits
FDA Drug Safety Communication: Safety Review update on reports of Hepatosplenic T-Cell Lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine
fda.gov —
[04-14-2011] The U.S. Food and Drug Administration (FDA) is informing the public that it continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL), primarily in adolescents and young adults being treated for Crohn--™s disease and ulcerative colitis with medicines known as tumor necrosis factor (TNF) blockers, as well as with azathioprine, and/or mercaptopurine.
View full resource at fda.gov
Tags: Crohn's Disease Medication, Lymphoma, Non-Hodgkin Lymphoma, Drug, FDA, Imuran, Safety
Most Recently Shared on April 14, 2011 at 3:51 pm By:
FDA ..Do you have patients taking tumor necrosis factor (TNF) blockers, azathioprine and/or mercaptopurine? Please read http://ow.ly/4AgL6
Advertisement
